|
Summary
October 2006, Vol. 2, No. 5, Pages 715-731
, DOI 10.1517/17425255.2.5.715
Preclinical formulations for discovery and toxicology: physicochemical challengesSeshadri NeervannanDirector, Small Molecule Pharmaceutics, Amgen, Inc., Mail Stop 8-2-D, One Amgen Center Drive, Thousand Oaks, CA 91320, USA. seshadri@amgen.com Formulations play a key role in assessing the biological properties of a molecule during drug discovery. Maximising exposure is the primary objective in early animal experimentation, so that the pharmacokinetics, pharmacodynamics and toxicological signals can be put into context with the biological response to specific targets. Consistency in the exposure is also a key aspect, and effective formulation and drug delivery strategies are important to achieve this. Diversity in the physiology between various animal species, routes of administration and limitations posed by specific pharmacological models make formulation development that much more challenging. Poor physicochemical properties of compounds in the early stages need to be kept under consideration while screening for formulation vehicles. This review captures the various challenges posed at different stages of drug discovery for formulation of a compound to dose in animals. Approaches to formulations for various routes of administration are discussed. Limitations posed by the goals for various animal studies such as early efficacy studies, pharmacokinetic studies and toxicology studies are identified and some strategies are proposed. Physicochemical characterisations that are needed to select formulation vehicles as well as to identify potential issues are suggested. Forward Links to Citing ArticlesW. Tang, R. A. Stearns, Q. Chen, K. Bleasby, Y. Teffera, A. Colletti, M. Hafey, R. Evers, D. C. Dean, P. A. Magriotis, T. J. Lanza, L. S. Lin, W. K. Hagmann, T. A. Baillie. (2008) Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. Xenobiotica 38:2, 223-237 Online publication date: 1-Feb-2008. Summary | Full Text | PDF (150 KB) | PDF Plus (192 KB) Jianling Wang, Laszlo Urban, Dejan Bojanic. (2007) Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opinion on Drug Metabolism & Toxicology 3:5, 641-665 Online publication date: 1-Oct-2007. Summary | Full Text | PDF (638 KB) | PDF Plus (943 KB) Users who read this article also read:
|
|





TOC Alert